This study demonstrated that GH-RH antagonists could be beneficial for the treatment of prostatic inflammation and BPH in part by inhibiting the growth-promoting and inflammatory effects of locally produced GH-RH95. Here, GHRH is linked to benign prostatic hyperplasia.